The necrotizing enterocolitis market is witnessing steady growth, primarily driven by the increasing incidence of preterm births worldwide, as premature infants are at the highest risk of developing NEC. Rising awareness among healthcare providers regarding early diagnosis and preventive care is further supporting market expansion. Additionally, ongoing research activities focused on novel therapeutics such as IBP-9414 (Infant Bacterial Therapeutics), STMC-106 (Siolta Therapeutics), ST266 (Noveome Biotherapeutics), Protego-PD (Plakous Therapeutics), and others, probiotics, stem cell therapies, and targeted interventions are creating significant growth opportunities.
The necrotizing enterocolitis market is witnessing steady growth, primarily driven by the increasing incidence of preterm births worldwide, as premature infants are at the highest risk of developing NEC. Rising awareness among healthcare providers regarding early diagnosis and preventive care is further supporting market expansion. Additionally, ongoing research activities focused on novel therapeutics such as IBP-9414 (Infant Bacterial Therapeutics), STMC-106 (Siolta Therapeutics), ST266 (Noveome Biotherapeutics), Protego-PD (Plakous Therapeutics), and others, probiotics, stem cell therapies, and targeted interventions are creating significant growth opportunities.